{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:09:30Z","timestamp":1777043370867,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Scientific Research Project of the Zhejiang Provincial Department of Education","award":["Y202454312"],"award-info":[{"award-number":["Y202454312"]}]},{"name":"The Scientific Research Project of the Zhejiang Provincial Department of Education","award":["Y202454312"],"award-info":[{"award-number":["Y202454312"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14302-w","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:17:01Z","timestamp":1747941421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying the germline variation spectrum and predisposition genes in Chinese ovarian cancer using whole exome sequencing"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaojing","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianyuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"2","key":"14302_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"14302_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"14302_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.5858\/arpa.2022-0166-RA","volume":"147","author":"V Parkash","year":"2023","unstructured":"Parkash V, Aisagbonhi O, Riddle N, Siddon A, Panse G, Fadare O. Recent Advances in the Classification of Gynecological Tract Tumors: Updates From the 5th Edition of the World Health Organization \u2018Blue Book.\u2019 Arch Pathol Lab Med. 2023;147(10):1204\u201316.","journal-title":"Arch Pathol Lab Med."},{"key":"14302_CR4","doi-asserted-by":"crossref","unstructured":"McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80(5):762\u201378.","DOI":"10.1111\/his.14609"},{"issue":"8","key":"14302_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/10408363.2023.2234488","volume":"60","author":"G Ponti","year":"2023","unstructured":"Ponti G, De Angelis C, Ponti R, Pongetti L, Losi L, Sticchi A, et al. Hereditary breast and ovarian cancer: from genes to molecular targeted therapies. Crit Rev Clin Lab Sci. 2023;60(8):640\u201350.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"7","key":"14302_CR6","doi-asserted-by":"publisher","first-page":"e2326437","DOI":"10.1001\/jamanetworkopen.2023.26437","volume":"6","author":"H Wen","year":"2023","unstructured":"Wen H, Xu Q, Sheng X, Li H, Wang X, Wu X. Prevalence and Landscape of Pathogenic or Likely Pathogenic Germline Variants and Their Association With Somatic Phenotype in Unselected Chinese Patients With Gynecologic Cancers. JAMA Netw Open. 2023;6(7):e2326437.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"14302_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1136\/ijgc-2020-001556","volume":"30","author":"A Pietragalla","year":"2020","unstructured":"Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A. Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. Int J Gynecol Cancer. 2020;30(11):1803\u201310.","journal-title":"Int J Gynecol Cancer"},{"key":"14302_CR8","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2024 Mar 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/"},{"issue":"3","key":"14302_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/cac2.12134","volume":"41","author":"R Ferrer-Avargues","year":"2021","unstructured":"Ferrer-Avargues R, Castillejo MI, D\u00e1maso E, D\u00edez-Obrero V, Garrigos N, Molina T, et al. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome. Cancer Commun (Lond). 2021;41(3):218\u201328.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"14302_CR10","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/jog.15273","volume":"48","author":"X Ran","year":"2022","unstructured":"Ran X, Jing H, Li Z. The clinical features and management of Lynch syndrome-associated ovarian cancer. J Obstet Gynaecol Res. 2022;48(7):1538\u201345.","journal-title":"J Obstet Gynaecol Res"},{"key":"14302_CR11","first-page":"1","volume":"20","author":"O Bahcall","year":"2013","unstructured":"Bahcall O. Common variation and heritability estimates for breast, ovarian and prostate cancers. Nat Genet. 2013;20:1\u20131.","journal-title":"Nat Genet"},{"issue":"1","key":"14302_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","volume":"39","author":"G Federici","year":"2020","unstructured":"Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J Exp Clin Cancer Res. 2020;39(1):46.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"14302_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2015.08.006","volume":"139","author":"MK Frey","year":"2015","unstructured":"Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, et al. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015;139(2):211\u20135.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"14302_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482\u201390.","journal-title":"JAMA Oncol"},{"issue":"8","key":"14302_CR15","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ijc.32545","volume":"146","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang R, et al. Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes. Int J Cancer. 2020;146(8):2147\u201355.","journal-title":"Int J Cancer"},{"key":"14302_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00066","volume":"1","author":"AW Kurian","year":"2017","unstructured":"Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman AR, et al. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precis Oncol. 2017;1:1\u201312.","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"14302_CR17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"10","key":"14302_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN, Churpek J, Kohlmann W, AlHilli Z, et al. NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024. J Natl Compr Canc Netw. 2023;21(10):1000\u201310.","journal-title":"J Natl Compr Canc Netw."},{"issue":"5","key":"14302_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"12","key":"14302_CR20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/gim.2016.39","volume":"18","author":"KS Park","year":"2016","unstructured":"Park KS, Cho EY, Nam SJ, Ki CS, Kim JW. Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. Genet Med. 2016;18(12):1250\u20137.","journal-title":"Genet Med"},{"issue":"6","key":"14302_CR21","first-page":"9420","volume":"15","author":"H Wei","year":"2018","unstructured":"Wei H, Wang M, Ou J, Jiang W, Tian F, Sheng Y, et al. Multicenter cross-sectional screening of the BRCA gene for Chinese high hereditary risk breast cancer populations. Oncol Lett. 2018;15(6):9420\u20138.","journal-title":"Oncol Lett"},{"issue":"6","key":"14302_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/genes11060622","volume":"11","author":"S Debnath","year":"2020","unstructured":"Debnath S, Sharma S. RECQ1 Helicase in Genomic Stability and Cancer. Genes (Basel). 2020;11(6):622.","journal-title":"Genes (Basel)"},{"issue":"1","key":"14302_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-021-06152-4","volume":"188","author":"P Lertwilaiwittaya","year":"2021","unstructured":"Lertwilaiwittaya P, Roothumnong E, Nakthong P, Dungort P, Meesamarnpong C, Tansa-Nga W, et al. Thai patients who fulfilled NCCN criteria for breast\/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing. Breast Cancer Res Treat. 2021;188(1):237\u201348.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"14302_CR24","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/ijc.30633","volume":"140","author":"T Shi","year":"2017","unstructured":"Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 2017;140(9):2051\u20139.","journal-title":"Int J Cancer"},{"issue":"21","key":"14302_CR25","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654\u201363.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14302_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"14302_CR27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4143\/crt.2017.220","volume":"50","author":"KJ Eoh","year":"2018","unstructured":"Eoh KJ, Kim JE, Park HS, Lee ST, Park JS, Han JW, et al. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1\/2. Cancer Res Treat. 2018;50(3):917\u201325.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"14302_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ygyno.2018.09.030","volume":"151","author":"NJ Carter","year":"2018","unstructured":"Carter NJ, Marshall ML, Susswein LR, Zorn KK, Hiraki S, Arvai KJ, et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol. 2018;151(3):481\u20138.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"14302_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13048-023-01119-z","volume":"16","author":"DS Prokofyeva","year":"2023","unstructured":"Prokofyeva DS, Mingazheva ET, Valova YV, Sakaeva DD, Faishanova RR, Nurgalieva AK, et al. Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan. J Ovarian Res. 2023;16(1):66.","journal-title":"J Ovarian Res"},{"issue":"6","key":"14302_CR30","doi-asserted-by":"publisher","first-page":"e0178450","DOI":"10.1371\/journal.pone.0178450","volume":"12","author":"JL Stafford","year":"2017","unstructured":"Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, et al. Reanalysis of BRCA1\/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS ONE. 2017;12(6):e0178450.","journal-title":"PLoS ONE"},{"issue":"1","key":"14302_CR31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41467-020-15461-z","volume":"11","author":"DN Subramanian","year":"2020","unstructured":"Subramanian DN, Zethoven M, McInerny S, Morgan JA, Rowley SM, Lee JEA, et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. Nat Commun. 2020;11(1):1640.","journal-title":"Nat Commun"},{"issue":"1","key":"14302_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ygyno.2018.07.024","volume":"151","author":"A Li","year":"2018","unstructured":"Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol. 2018;151(1):145\u201352.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"14302_CR33","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347\u201361.","journal-title":"JAMA"},{"issue":"3","key":"14302_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/humu.24158","volume":"42","author":"PS Felicio","year":"2021","unstructured":"Felicio PS, Grasel RS, Campacci N, de Paula AE, Galv\u00e3o HCR, Torrezan GT, et al. Whole-exome sequencing of non-BRCA1\/BRCA2 mutation carrier cases at high-risk for hereditary breast\/ovarian cancer. Hum Mutat. 2021;42(3):290\u20139.","journal-title":"Hum Mutat"},{"issue":"5","key":"14302_CR35","doi-asserted-by":"publisher","first-page":"e62481","DOI":"10.1371\/journal.pone.0062481","volume":"8","author":"S Parvathaneni","year":"2013","unstructured":"Parvathaneni S, Stortchevoi A, Sommers JA, Brosh RM, Sharma S. Human RECQ1 interacts with Ku70\/80 and modulates DNA end-joining of double-strand breaks. PLoS ONE. 2013;8(5):e62481.","journal-title":"PLoS ONE"},{"issue":"9","key":"14302_CR36","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1093\/nar\/gku200","volume":"42","author":"V Popuri","year":"2014","unstructured":"Popuri V, Hsu J, Khadka P, Horvath K, Liu Y, Croteau DL, et al. Human RECQL1 participates in telomere maintenance. Nucleic Acids Res. 2014;42(9):5671\u201388.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"14302_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2016.5592","volume":"3","author":"G Neidhardt","year":"2017","unstructured":"Neidhardt G, Hauke J, Ramser J, Gro\u00df E, Gehrig A, M\u00fcller CR, et al. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncol. 2017;3(9):1245\u20138.","journal-title":"JAMA Oncol"},{"issue":"7","key":"14302_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/tra.12069","volume":"14","author":"AR Cullinane","year":"2013","unstructured":"Cullinane AR, Sch\u00e4ffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic. 2013;14(7):749\u201366.","journal-title":"Traffic"},{"key":"14302_CR39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fgene.2019.01005","volume":"10","author":"S Glentis","year":"2019","unstructured":"Glentis S, Dimopoulos AC, Rouskas K, Ntritsos G, Evangelou E, Narod SA, et al. Exome Sequencing in BRCA1- and BRCA2-Negative Greek Families Identifies MDM1 and NBEAL1 as Candidate Risk Genes for Hereditary Breast Cancer. Front Genet. 2019;10:1005.","journal-title":"Front Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14302-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14302-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:17:05Z","timestamp":1747941425000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14302-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14302"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14302-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research adhered to the Helsinki Declaration and was approved by the ethics committee of the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. All patients provided written informed consent to use their clinical information for research purposes. All experiments were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"924"}}